letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...7778798081828384858687...100101»
  • ||||||||||  letrozole / Generic mfg.
    Trial primary completion date, Combination therapy:  Study of Letrozole in Recurrent Gliomas (clinicaltrials.gov) -  Oct 1, 2018   
    P1,  N=12, Recruiting, 
    Trial completion date: Sep 2021 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Jun 2019 Trial primary completion date: Apr 2018 --> Apr 2019
  • ||||||||||  Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) -  Sep 28, 2018   
    P2,  N=7, Active, not recruiting, 
    Trial primary completion date: Apr 2018 --> Apr 2019 Recruiting --> Active, not recruiting | N=32 --> 7 | Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Enrollment closed, Metastases:  MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) -  Sep 20, 2018   
    P3,  N=450, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=32 --> 7 | Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018 Recruiting --> Active, not recruiting
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg., everolimus / Generic mfg.
    Trial primary completion date, Metastases:  Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer (clinicaltrials.gov) -  Sep 18, 2018   
    P2,  N=74, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Dec 2017 --> Mar 2018 Trial primary completion date: Jun 2017 --> Jan 2018
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Orbital fat regeneration following hormonal treatment of metastatic breast carcinoma. (Pubmed Central) -  Sep 2, 2018   
    Treatment with an aromatase inhibitor (letrozole) resulted in tumor regression and orbital fat restoration with a corresponding improvement in orbital volume and enophthalmos on clinical exam...This case illustrates the resilience of orbital soft tissues and ability of orbital fat to regenerate in face of breast cancer metastasis. We hypothesize that endocrine monotherapy, and avoidance of radiation therapy, allowed for differentiation of remaining orbital stem cells, and facilitated the fat regenerative process.
  • ||||||||||  letrozole / Generic mfg.
    Enrollment closed:  Brovale: Fertility Preservation in Breast Cancer Patients (clinicaltrials.gov) -  Aug 28, 2018   
    P4,  N=65, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
    Trial completion date, Trial primary completion date:  NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) -  Jul 27, 2018   
    P2,  N=32, Recruiting, 
    Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019 Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Jul 2018
  • ||||||||||  Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
    Enrollment closed, Trial completion date, Trial primary completion date:  PER-ELISA: Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy (clinicaltrials.gov) -  Jul 20, 2018   
    P2,  N=68, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2020 | Trial primary completion date: Feb 2018 --> Dec 2019 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Oct 2017 --> Oct 2018
  • ||||||||||  letrozole / Generic mfg., cyclophosphamide / Generic mfg.
    Trial completion date, Trial primary completion date:  Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients (clinicaltrials.gov) -  Jul 19, 2018   
    P=N/A,  N=200, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Oct 2017 --> Oct 2018 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Sep 2018 --> Sep 2019
  • ||||||||||  Ibrance (palbociclib) / Pfizer, dinaciclib (PS-095760) / Ligand, Merck (MSD)
    Journal:  Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. (Pubmed Central) -  Jul 18, 2018   
    Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2018 --> Aug 2017 Collectively, these findings suggest that cell cycle deregulation by LMW-E mediates resistance to AIs and a combination of CDK2 inhibitors and AIs may be an effective treatment in patients with HR-positive tumors that express LMW-E.